Post on 22-Feb-2016
description
Cardiovascular Outcomes Trials in Diabetes: The Truth, the Whole
Truth, and Nothing But the Truth
Program Goals
The Growing Diabetes Pandemic
Approved Antidiabetic Medications
Cardiovascular benefits to tighter HbA1c control?
Outcomes of Better Glycemic Control in T2D: UKPDS and Post-
UKPDS
Should Hyperglycemia in Diabetes Be Treated Aggressively?
DCCT/EDIC: Intensive Diabetes Therapy in T1D
Counseling a Patient With Newly Diagnosed T2D
Sulfonylureas
Safety of Sulfonylureas
Safety of Sulfonylureas (cont)
The CAROLINA Study: Phase 3 Results
Rosiglitazone Data Reanalyzed
Results of a Reevaluation of Cardiovascular Outcomes in the
RECORD Trial
Thiazolidinediones
Pioglitazone: The PROactive Study
Guidance for Industry: Diabetes Mellitus -- Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat T2D
Impact of FDA Guidance: December 2008
Incretin-Based Drugs
Incretin-Based Drugs (cont)
Warnings and Precautions
SGLT-2 Inhibitors
SGLT-2 Inhibitors (cont)
SAVOR-TIMI 53 trial
Take-Home Messages
Abbreviations
Abbreviations (cont)
Abbreviations (cont)
References
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)